AB1518
Anti-Neurofibrillary Tangles Antibody
serum, Chemicon®
Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)
About This Item
UNSPSC-Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Empfohlene Produkte
Biologische Quelle
rabbit
Qualitätsniveau
Antikörperform
serum
Antikörper-Produkttyp
primary antibodies
Klon
polyclonal
Speziesreaktivität
human
Hersteller/Markenname
Chemicon®
Methode(n)
ELISA: suitable
immunohistochemistry (formalin-fixed, paraffin-embedded sections): suitable
western blot: suitable
Versandbedingung
dry ice
Posttranslationale Modifikation Target
unmodified
Spezifität
Specifically stains neurofibrillary tangles and degenerating plaque neurites in cases of Alzheimer′s disease, Down′s Syndrome and normal aged individuals.
Immunogen
Neurofibrillary tangles which were extracted in boiling SDS and purified by sucrose gradient centrifugation.
Anwendung
Research Category
Neurowissenschaft
Neurowissenschaft
Research Sub Category
Neurodegenerative Krankheiten
Neurodegenerative Krankheiten
Anti-Neurofibrillary Tangles Antibody is an antibody against Neurofibrillary Tangles for use in ELISA, WB, IH, IH(P).
Immunohistochemistry on paraffin, vibratome and frozen sections: ≥1:200, ≥1:2,000, respectively.
Western blotting: ≥1:500.
ELISA using immunogen peptide: ≥1:4,000.
Optimal working dilutions must be determined by end user.
Western blotting: ≥1:500.
ELISA using immunogen peptide: ≥1:4,000.
Optimal working dilutions must be determined by end user.
Physikalische Form
Rabbit antisera with 0.01% thimerosal.
Lagerung und Haltbarkeit
Store at -20°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles.
Rechtliche Hinweise
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Haftungsausschluss
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Sie haben nicht das passende Produkt gefunden?
Probieren Sie unser Produkt-Auswahlhilfe. aus.
Lagerklassenschlüssel
10 - Combustible liquids
WGK
WGK 1
Analysenzertifikate (COA)
Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.
Besitzen Sie dieses Produkt bereits?
In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.
Reducing amyloid-related Alzheimer's disease pathogenesis by a small molecule targeting filamin A.
Wang, HY; Bakshi, K; Frankfurt, M; Stucky, A; Goberdhan, M; Shah, SM; Burns, LH
The Journal of Neuroscience null
Milena Penkowa et al.
Journal of neuroscience research, 77(1), 35-53 (2004-06-16)
Transgenic expression of interleukin-6 (IL-6) in the CNS under the control of the glial fibrillary acidic protein (GFAP) gene promoter (GFAP-IL6 mice) induces significant inflammation and neurodegeneration but also affords neuroprotection against acute traumatic brain injury. This neuroprotection is likely
Focal expression of mutated tau in entorhinal cortex neurons of rats impairs spatial working memory.
Julio J Ramirez et al.
Behavioural brain research, 216(1), 332-340 (2010-08-24)
Entorhinal cortex neuropathology begins very early in Alzheimer's disease (AD), a disorder characterized by severe memory disruption. Indeed, loss of entorhinal volume is predictive of AD and two of the hallmark neuroanatomical markers of AD, amyloid plaques and neurofibrillary tangles
Leslie Vargas-Saturno et al.
The European journal of neuroscience, 48(12), 3514-3533 (2018-11-08)
Understanding endogenous neurogenesis and neuronal replacement to mature circuits is a topic of discussion as a therapeutic alternative under acute and chronic neurodegenerative disorders. Adaptive neurogenic response may result as a result of ischemia which could support long-term recovery of
Martina L Mustroph et al.
Behavioural brain research, 233(1), 141-148 (2012-05-09)
Tauopathy in the hippocampus is one of the earliest cardinal features of Alzheimer's disease (AD), a condition characterized by progressive memory impairments. In fact, density of tau neurofibrillary tangles (NFTs) in the hippocampus strongly correlates with severity of cognitive impairments
Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..
Setzen Sie sich mit dem technischen Dienst in Verbindung.